Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented an analysis from the Phase 2 ...

New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit ...

The Lewy Body Society is pleading with the government and the NHS not to let Lewy body dementia continue being the “forgotten dementia”. In Dementia Action Week (19 - 25 May 2025), Jacqui Cannon, CEO ...

Please provide your email address to receive an email when new articles are posted on . The introduction of additional neflamapimod in an open-label extension led to significant clinical improvements.

After her mom's diagnosis of Lewy body dementia, a Lincoln woman said she noticed there was a lack of culturally diverse support options in Nebraska. Now, she's working to raise awareness and be part ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

Please provide your email address to receive an email when new articles are posted on . In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association ...

Studies headed by researchers at Johns Hopkins Medicine have uncovered a possible molecular connection between air pollution and an increased risk of developing Lewy body dementia (LBD). The team ...

She looked at me with tears in her eyes, and I said, “Isn’t it nice to love someone so much that saying goodbye is so hard?” Her face relaxed, as if through the disease she was able to grasp a moment ...